The Role of Contrast-Enhanced Imaging for Colorectal Cancer Management
- 10 Downloads
Purpose of Review
Imaging is fundamental in the management of colorectal cancer (CRC). Contrast-enhanced computed tomography (CECT) and contrast-enhanced magnetic resonance (CEMR) are the imaging modalities recommended to stage and restage CRC. The aim of this review is to summarize the most relevant studies published on the role of contrast-enhanced imaging for the management of CRC.
There are published data demonstrating the accuracy of CECT and CEMR for local staging of both colon and rectal cancer, as well as for the evaluation of distant metastases. Moreover, different aspects of these methods, in particular perfusion techniques, are emerging as prognostic biomarkers. The optimization of contrast media injection protocols is essential to ensure reproducibility and high image quality.
Contrast-enhanced imaging is mandatory in the management of CRC both for the evaluation of the primary tumor and of distant metastases.
KeywordsContrast-enhanced computed tomography Perfusion magnetic resonance imaging Colorectal cancer Cancer staging Biomarkers Multimodal imaging
Contrast-enhanced computed tomography
Computed tomography colonography
Computed tomography perfusion
Contrast-enhanced magnetic resonance
Dynamic contrast-enhanced magnetic resonance
Extramural venous invasion
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Ganeshan, D., et al., Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol (NY), 2019. Interesting review focused on the role of the radiologist for the evaluation of recurrent rectal cancer. Google Scholar
- 6.Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–60.Google Scholar
- 7.Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options in Oncol. 2016;17(6):32.Google Scholar
- 9.Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Correction to: Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(6):2711.PubMedPubMedCentralGoogle Scholar
- 14.•• Park SY, et al. Diagnostic performance of MRI- versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdom Radiol (NY). 2019;44(5):1675–85 Small but very insteresting paper comparing CT and MRI for the risk assessment of colon cancer. Google Scholar
- 19.Hospers GA, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol. 2007;14(10):2773–9.PubMedPubMedCentralGoogle Scholar
- 32.Kim YE, Lim JS, Choi J, Kim D, Myoung S, Kim MJ, et al. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging in patients with rectal cancer: correlation with microvascular density and vascular endothelial growth factor expression. Korean J Radiol. 2013;14(6):878–85.PubMedPubMedCentralGoogle Scholar
- 33.Ciolina M, et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: role of perfusion parameters in the assessment of response to treatment. Radiol Med. 2018.Google Scholar
- 63.Benson AB, Venook AP, al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Cancer Netw. 2018;16(4):359–69.Google Scholar
- 64.Benson AB, Venook AP, al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(7):874–901.Google Scholar
- 65.Benson AB, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(3):370–98.Google Scholar
- 66.Rengo M, Caruso D, de Cecco CN, Lucchesi P, Bellini D, Maceroni MM, et al. High concentration (400 mgI/mL) versus low concentration (320 mgI/mL) iodinated contrast media in multi detector computed tomography of the liver: a randomized, single centre, non-inferiority study. Eur J Radiol. 2012;81(11):3096–101.PubMedGoogle Scholar
- 68.Rengo M, Bellini D, Businaro R, Caruso D, Azzara G, de Santis D, et al. MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose. Abdom Radiol (NY). 2017;42(10):2420–7.Google Scholar
- 69.Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Phys. 1984;247(4 Pt 2):F632–6.Google Scholar
- 77.• Beckers RCJ, et al. Advanced imaging to predict response to chemotherapy in colorectal liver metastases - a systematic review. HPB (Oxford). 2018;20(2):120–7 Very interesting paper demotrating the role of advance imaging for the management of liver metastases in colorectal cancer. Google Scholar
- 84.•• Laghi A, et al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med. 2017;122(1):1–15 Very interesting meta-analysis demostrating the role of CT and MRI for the evaluation of peritoneal carcinosis. PubMedGoogle Scholar